Cargando…

Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not

Background: Accurate determination of human epidermal growth factor receptor 2 (HER2) status on breast core needle biopsy (CNB) tissue is important for determining neoadjuvant chemotherapies (NACs) for primary breast cancer. However, HER2 discrepancies occur before and after surgery, creating diffic...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Young-Hoon, Hong, Soon Auck, Ahn, Hye Shin, Ahn, Soo kyung, Kim, Min Kyoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210558/
https://www.ncbi.nlm.nih.gov/pubmed/34149935
http://dx.doi.org/10.7150/jca.59419
_version_ 1783709335911661568
author Jeong, Young-Hoon
Hong, Soon Auck
Ahn, Hye Shin
Ahn, Soo kyung
Kim, Min Kyoon
author_facet Jeong, Young-Hoon
Hong, Soon Auck
Ahn, Hye Shin
Ahn, Soo kyung
Kim, Min Kyoon
author_sort Jeong, Young-Hoon
collection PubMed
description Background: Accurate determination of human epidermal growth factor receptor 2 (HER2) status on breast core needle biopsy (CNB) tissue is important for determining neoadjuvant chemotherapies (NACs) for primary breast cancer. However, HER2 discrepancies occur before and after surgery, creating difficulties in the administration of appropriate NAC. This study aimed to identify the clinical factors affecting these discrepancies. Methods: This study was conducted on patients with primary breast cancer who underwent breast surgery from January 2012 to December 2018 at the Chung-Ang University Hospital. HER2 status was analyzed using immunohistochemistry. HER2 was graded as 0 to +3, and all 2+ cases were evaluated for gene amplification. The patients were divided into two groups based on whether or not they received chemotherapy. Patient and clinical characteristics between the two groups were compared using the χ2 test and a logistic regression model. Results: A total of 443 patients were evaluated; 384 patients (86.7%) did not receive NAC, and 59 patients (13.3%) received NAC. The HER2 discordance rate was 12.5% in the no NAC group and 23.7% in the NAC group. Most cases showed a change in HER2 status from negative in CNB to positive in surgical biopsy (SB). Clinicopathological factors affecting HER2 change in the no NAC group were larger tumor size and higher histologic grade. Meanwhile, poor response to prior chemotherapy affected HER2 change in NAC. Conclusion: The overall accuracy of CNB in determining HER2 status was lower in the NAC group than in the no NAC group. Some clinicopathological factors may affect HER2 changes in each group at different levels. Based on the HER2 status at the time of diagnosis, the choice of HER2-targeted therapy may vary, even if this is not true. Future research on the effects of changes in HER2 status between CNB and SB on prognosis is needed.
format Online
Article
Text
id pubmed-8210558
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-82105582021-06-17 Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not Jeong, Young-Hoon Hong, Soon Auck Ahn, Hye Shin Ahn, Soo kyung Kim, Min Kyoon J Cancer Research Paper Background: Accurate determination of human epidermal growth factor receptor 2 (HER2) status on breast core needle biopsy (CNB) tissue is important for determining neoadjuvant chemotherapies (NACs) for primary breast cancer. However, HER2 discrepancies occur before and after surgery, creating difficulties in the administration of appropriate NAC. This study aimed to identify the clinical factors affecting these discrepancies. Methods: This study was conducted on patients with primary breast cancer who underwent breast surgery from January 2012 to December 2018 at the Chung-Ang University Hospital. HER2 status was analyzed using immunohistochemistry. HER2 was graded as 0 to +3, and all 2+ cases were evaluated for gene amplification. The patients were divided into two groups based on whether or not they received chemotherapy. Patient and clinical characteristics between the two groups were compared using the χ2 test and a logistic regression model. Results: A total of 443 patients were evaluated; 384 patients (86.7%) did not receive NAC, and 59 patients (13.3%) received NAC. The HER2 discordance rate was 12.5% in the no NAC group and 23.7% in the NAC group. Most cases showed a change in HER2 status from negative in CNB to positive in surgical biopsy (SB). Clinicopathological factors affecting HER2 change in the no NAC group were larger tumor size and higher histologic grade. Meanwhile, poor response to prior chemotherapy affected HER2 change in NAC. Conclusion: The overall accuracy of CNB in determining HER2 status was lower in the NAC group than in the no NAC group. Some clinicopathological factors may affect HER2 changes in each group at different levels. Based on the HER2 status at the time of diagnosis, the choice of HER2-targeted therapy may vary, even if this is not true. Future research on the effects of changes in HER2 status between CNB and SB on prognosis is needed. Ivyspring International Publisher 2021-06-04 /pmc/articles/PMC8210558/ /pubmed/34149935 http://dx.doi.org/10.7150/jca.59419 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Jeong, Young-Hoon
Hong, Soon Auck
Ahn, Hye Shin
Ahn, Soo kyung
Kim, Min Kyoon
Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not
title Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not
title_full Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not
title_fullStr Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not
title_full_unstemmed Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not
title_short Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not
title_sort clinicopathologic factors affecting discrepancies in her2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210558/
https://www.ncbi.nlm.nih.gov/pubmed/34149935
http://dx.doi.org/10.7150/jca.59419
work_keys_str_mv AT jeongyounghoon clinicopathologicfactorsaffectingdiscrepanciesinher2overexpressionbetweencoreneedlebiopsyandsurgicalbiopsyinbreastcancerpatientsaccordingtoneoadjuvanttreatmentornot
AT hongsoonauck clinicopathologicfactorsaffectingdiscrepanciesinher2overexpressionbetweencoreneedlebiopsyandsurgicalbiopsyinbreastcancerpatientsaccordingtoneoadjuvanttreatmentornot
AT ahnhyeshin clinicopathologicfactorsaffectingdiscrepanciesinher2overexpressionbetweencoreneedlebiopsyandsurgicalbiopsyinbreastcancerpatientsaccordingtoneoadjuvanttreatmentornot
AT ahnsookyung clinicopathologicfactorsaffectingdiscrepanciesinher2overexpressionbetweencoreneedlebiopsyandsurgicalbiopsyinbreastcancerpatientsaccordingtoneoadjuvanttreatmentornot
AT kimminkyoon clinicopathologicfactorsaffectingdiscrepanciesinher2overexpressionbetweencoreneedlebiopsyandsurgicalbiopsyinbreastcancerpatientsaccordingtoneoadjuvanttreatmentornot